PMA supplement
P210036 S007: PerClot® Polysaccharide Hemostatic System
FDA PMA supplement · Normal 180 Day Track No User Fee · Baxter Healthcare Corporation
Key facts
| Original PMA | P210036 |
|---|---|
| Supplement number | S007 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Location Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | PerClot® Polysaccharide Hemostatic System |
| Generic name | Agent, absorbable hemostatic, non-collagen based |
| Applicant | Baxter Healthcare Corporation |
| Product code | LMG |
| Received date | Dec 23, 2025 |
| Decision date | Jun 8, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: